Trial Profile

The Bihormonal iLet Bionic Pancreas Feasibility Study

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasiglucagon (Primary) ; Insulin aspart (Primary) ; Insulin lispro (Primary)
Indications Type 1 diabetes mellitus
Focus First in man; Therapeutic Use

Most Recent Events

25 Sep 2020 Results (n=10) assessing individual response of automated glycaemic control with iLet bionic pancreas in insulin-only versus bihormonal configuration presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
27 Nov 2019 Status changed from active, no longer recruiting to completed.
05 Jun 2019 According to an Beta Bionics, Zealand Pharma A/S Media Release, the bihormonal iLet Bionic Pancreas System demonstrated tight glycemic control in a home-use setting with dasiglucagon. The company looks forward to proceeding with the Phase 3 part of the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com